<SEC-DOCUMENT>0001193125-23-090871.txt : 20230404
<SEC-HEADER>0001193125-23-090871.hdr.sgml : 20230404
<ACCEPTANCE-DATETIME>20230404161611
ACCESSION NUMBER:		0001193125-23-090871
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230404
DATE AS OF CHANGE:		20230404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SYNLOGIC, INC.
		CENTRAL INDEX KEY:			0001527599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261824804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258151
		FILM NUMBER:		23797668

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-401-9975

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mirna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20110809
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d461330d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed Pursuant to Rule 424(b)(5) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-258151</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To the Prospectus dated
July&nbsp;30, 2021) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$16,415,139 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Synlogic, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement amends and supplements the information in our prospectus dated July&nbsp;30, 2021 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-258151).</FONT> This prospectus supplement should be read in conjunction with the prospectus and is qualified in its entirety by reference thereto, except to the extent that the information herein amends
or supersedes the information contained in the prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the prospectus and any future amendments or supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We filed the prospectus to register the offer and sale of shares of our common stock from time to time pursuant to the terms of a sales agreement, dated
July&nbsp;23, 2021 that we entered into with Jefferies LLC, or Jefferies, as our sales agent thereunder. As of the date of this prospectus supplement, we have sold an aggregate of 1,514,849 shares of our common stock through Jefferies under the
sales agreement, resulting in net proceeds of approximately $1.2&nbsp;million. Without giving effect to any offering limit imposed by General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> we may offer and sell shares of our
common stock having an aggregate offering price of up to $50,000,000 from time to time through Jefferies acting as our sales agent in accordance with the terms of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement, including the shares of common stock that we have sold as of the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2023, the date on which we filed our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2022, the prospectus became subject to the offering limits set forth in General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As of March&nbsp;29, 2023, the aggregate market value of our outstanding common
stock held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or public float, was approximately $49,245,416, based on 54,115,842 shares of our outstanding common stock that were held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
on such date and a price of $0.91 per share, which was the price at which our common stock was last sold on The Nasdaq Global Market on February&nbsp;3, 2023 (a date within 60 days of the date hereof), calculated in accordance with General
Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> We have not offered any securities pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> in the 12 calendar months preceding the date of this
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are filing this prospectus supplement to amend and supplement the information in our prospectus based on the amount of
securities that we are eligible to sell under General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> After giving effect to the $16,415,139 offering limit imposed by General Instruction I.B.6 of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> we may offer and sell additional shares of our common stock having an aggregate offering price of up to $16,415,139 from time to time through Jefferies acting as our sales agent in accordance with the terms of
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on The Nasdaq Global Market under the symbol &#147;SYBX.&#148; On April&nbsp;3, 2023, the last reported sale price of our common stock on The Nasdaq Global Market was $0.58 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risks. You should read this prospectus supplement and the documents we incorporate herein by reference carefully
before you make your investment decision. See &#147;Risk Factors&#148; set forth in the documents we file with the Securities and Exchange Commission that are incorporated by reference herein for more information. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement dated April&nbsp;4, 2023. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
